Feb 13, 2026, 12:00 AM
Integrative single-cell analysis uncovers distinct tumour microenvironment ecotypes and immune evasion across skin cancers
Background: Skin cancers, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), cutaneous melanoma (CM) and acral melanoma (AM), exhibit profound heterogeneity in clinical behaviour and…
Impact of C. albicans on melanoma cells: use of antifungal therapies as complementary to traditional treatments for melanoma
Recent studies have increasingly focused on the role of fungi, including Candida albicans, in carcinogenesis. Since C. albicans is a component of the human microbiota, particularly on the skin, we inv…
Non-melanoma skin cancer in transplant recipients: need for sustained, long-term dermatologic surveillance, particularly in older patients
Background: Non-melanoma skin cancer (NMSC) is a frequent long-term complication in transplant recipients, mainly due to chronic immunosuppression. Its incidence varies by transplant type and regimen…
Neoadjuvant pembrolizumab in individuals with resectable desmoplastic melanoma results in a high pCR rate with acceptable safety profile (phase 2 SWOG S1512 trial)
The phase 2 SWOG S1512 trial (NCT02775851) was designed to evaluate the response to pembrolizumab (anti-PD-1) in individuals with desmoplastic melanoma. Here we report the results of cohort A of the t…
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial
Neoadjuvant ipilimumab plus nivolumab has become standard therapy for stage III melanoma based on the NADINA trial, although long-term data are lacking. In the phase 2 PRADO cohort of OpACIN-neo, 99 p…
Implementation of ultrasound and fine-needle aspiration cytology (FNAC) prior to sentinel lymph node biopsy in melanoma enables neoadjuvant immunotherapy and is cost saving
Background: Neoadjuvant immunotherapy improves outcomes compared to adjuvant therapy in stage III melanoma and reduces costs when adjuvant therapy is omitted following a major pathological response (M…
Chimeric antigen receptor (CAR) engineered T-cell immunotherapy of malignant melanoma
Introduction: Management of inoperable and advanced malignant melanoma has been transformed in recent years by the advent of a number of approaches, including immune checkpoint blockade, small-molecul…
Skin cancer in residential care facilities: review of risk, diagnosis, psychosocial impact, and management
The older adult population is rising, resulting in a larger number of adults residing in nursing homes. Skin cancer is most commonly diagnosed in older adults. Yet, these individuals often face limite…
GLUT1 expression, lymphocyte distribution and CD3+ T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma
Background: Glycolysis, commonly used by malignant tumors for energy production, results in acidification of the tumor microenvironment (TME) through the secretion and accumulation of lactic acid. Aci…
Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma
Tumour mutation burden (TMB) is a promising biomarker in predicting immunotherapy response, yet its reproducibility across target panels needs to be established. This study assessed the reproducibilit…